A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Hájek, R, Masszi, T, Petrucci, M T, Palumbo, A, Rosiñol, L, Nagler, A, Yong, K L, Oriol, A, Minarik, J, Pour, L, Dimopoulos, M A, Maisnar, V, Rossi, D, Kasparu, H, Van Droogenbroeck, J, Yehuda, D B, Hardan, I, Jenner, M, Calbecka, M, Dávid, M, de la Rubia, J, Drach, J, Gasztonyi, Z, Górnik, S, Leleu, X, Munder, M, Offidani, M, Zojer, N, Rajangam, K, Chang, Y-L, San-Miguel, J F, Ludwig, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220126/
https://www.ncbi.nlm.nih.gov/pubmed/27416912
http://dx.doi.org/10.1038/leu.2016.176

Ejemplares similares

Ejemplares similares